Dossier assessment

Pirtobrutinib (CLL) – Benefit assessment according to §35a Social Code Book V

Report documents

Indication:

Adult patients with relapsed or refractory chronic lymphocytic leukaemia

Result of dossier assessment:

Patients who have been previously treated with a Bruton’s tyrosine kinase inhibitor and not with a B-cell lymphoma 2 inhibitor: added benefit not proven
Patients who have been previously treated with a Bruton’s tyrosine kinase inhibitor and a B-cell lymphoma 2 inhibitor: added benefit not proven

Project no.: A25-50
Commission: Commission awarded on 10.04.2025 by the Federal Joint Committee (GBA).
Report type: Dossier assessment
Status: Commission completed
Department/Division: Drug Assessment
Topic: Cancer
Note: After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
DOI: https://doi.org/10.60584/A25-50_en

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.